G Roberts1, P J Anderson, L W Doyle. 1. Department of Obstetrics and Gynaecology, The Royal Women's Hospital, 20 Flemington Road, Parkville, VIC 3052, Australia. gehan.roberts@rch.org.au
Abstract
OBJECTIVE: Studies reporting the developmental outcomes for very preterm (VPT) children often focus on development at age 2 years. The aim of this study was to assess the stability of the rates of diagnosis of developmental disability from age 2 to 8 years in a regional cohort of VPT and extremely low-birth weight (ELBW) children and compare these with term controls. METHODS: VPT (22-27 completed weeks of gestation) and ELBW (birth weight 500-999 g) children and matched term controls born in Victoria, Australia, in 1997 were enrolled at birth in a regional prospective longitudinal study. Outcomes were assessed at ages 2 and 8 years. RESULTS: Of the 283 VPT/ELBW live births, 71% survived to age 8 years and 94% were assessed. Of the 199 controls, 100% survived to age 8 years and 86.9% were assessed. At age 2 years, the rates of nil, mild, moderate and severe disabilities in the VPT/ELBW children were respectively 51.9%, 20.9%, 13.4% and 13.9%; and at age 8 years, 43.9%, 36.9%, 10.7% and 8.6%. The Cohen κ statistic revealed poor agreement between disability status at ages 2 and 8 years for VPT/ELBW children (0.20, p<0.001) but a higher level of agreement (0.37, p<0.001) for the control children. This was primarily driven by differences in classification of cognitive disability between ages 2 and 8 years. CONCLUSIONS: Developmental outcomes at age 2 years are only a moderate predictor of long-term outcome and are not a reliable end point for follow-up studies of VPT and ELBW children.
OBJECTIVE: Studies reporting the developmental outcomes for very preterm (VPT) children often focus on development at age 2 years. The aim of this study was to assess the stability of the rates of diagnosis of developmental disability from age 2 to 8 years in a regional cohort of VPT and extremely low-birth weight (ELBW) children and compare these with term controls. METHODS: VPT (22-27 completed weeks of gestation) and ELBW (birth weight 500-999 g) children and matched term controls born in Victoria, Australia, in 1997 were enrolled at birth in a regional prospective longitudinal study. Outcomes were assessed at ages 2 and 8 years. RESULTS: Of the 283 VPT/ELBW live births, 71% survived to age 8 years and 94% were assessed. Of the 199 controls, 100% survived to age 8 years and 86.9% were assessed. At age 2 years, the rates of nil, mild, moderate and severe disabilities in the VPT/ELBW children were respectively 51.9%, 20.9%, 13.4% and 13.9%; and at age 8 years, 43.9%, 36.9%, 10.7% and 8.6%. The Cohen κ statistic revealed poor agreement between disability status at ages 2 and 8 years for VPT/ELBW children (0.20, p<0.001) but a higher level of agreement (0.37, p<0.001) for the control children. This was primarily driven by differences in classification of cognitive disability between ages 2 and 8 years. CONCLUSIONS: Developmental outcomes at age 2 years are only a moderate predictor of long-term outcome and are not a reliable end point for follow-up studies of VPT and ELBW children.
Authors: T Michael O'Shea; Elizabeth N Allred; Karl C K Kuban; Olaf Dammann; Nigel Paneth; Raina Fichorova; Deborah Hirtz; Alan Leviton Journal: J Pediatr Date: 2011-10-13 Impact factor: 4.406
Authors: Alicia J Spittle; Jeanie Cheong; Lex W Doyle; Gehan Roberts; Katherine J Lee; Jeremy Lim; Rod W Hunt; Terrie E Inder; Peter J Anderson Journal: Dev Med Child Neurol Date: 2011-11 Impact factor: 5.449
Authors: Betty R Vohr; Bonnie E Stephens; Rosemary D Higgins; Carla M Bann; Susan R Hintz; Abhik Das; Jamie E Newman; Myriam Peralta-Carcelen; Kimberly Yolton; Anna M Dusick; Patricia W Evans; Ricki F Goldstein; Richard A Ehrenkranz; Athina Pappas; Ira Adams-Chapman; Deanne E Wilson-Costello; Charles R Bauer; Anna Bodnar; Roy J Heyne; Yvonne E Vaucher; Robert G Dillard; Michael J Acarregui; Elisabeth C McGowan; Gary J Myers; Janell Fuller Journal: J Pediatr Date: 2012-03-14 Impact factor: 4.406
Authors: Rachel G Greenberg; Daniel K Benjamin; Marie G Gantz; C Michael Cotten; Barbara J Stoll; Michele C Walsh; Pablo J Sánchez; Seetha Shankaran; Abhik Das; Rosemary D Higgins; Nancy A Miller; Kathy J Auten; Thomas J Walsh; Abbot R Laptook; Waldemar A Carlo; Kathleen A Kennedy; Neil N Finer; Shahnaz Duara; Kurt Schibler; Richard A Ehrenkranz; Krisa P Van Meurs; Ivan D Frantz; Dale L Phelps; Brenda B Poindexter; Edward F Bell; T Michael O'Shea; Kristi L Watterberg; Ronald N Goldberg; P Brian Smith Journal: J Pediatr Date: 2012-03-15 Impact factor: 4.406
Authors: T Michael O'Shea; Robert M Joseph; Karl C K Kuban; Elizabeth N Allred; Janice Ware; Taryn Coster; Raina N Fichorova; Olaf Dammann; Alan Leviton Journal: Pediatr Res Date: 2014-04-10 Impact factor: 3.756
Authors: T Michael O'Shea; Bhavesh Shah; Elizabeth N Allred; Raina N Fichorova; Karl C K Kuban; Olaf Dammann; Alan Leviton Journal: Brain Behav Immun Date: 2013-01-04 Impact factor: 7.217